Your session is about to expire
← Back to Search
IMM2902 for Solid Tumors
Study Summary
This trial is testing a new drug, IMM2902, to see if it is safe and effective in treating patients with advanced solid tumors that express the HER2 protein.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- My lung, kidney, or liver function is stable.I have a known bleeding disorder.I am not pregnant or cannot become pregnant, confirmed by a recent test.I have received high doses of anthracyclines for my cancer.My cancer expresses HER2 and I've had or refused treatment, with no cure available.I have a specific heart condition.I need blood-thinning medication for my condition, but not in all cases.I don't have lasting side effects from cancer treatment worse than Grade 2.I have a tumor that can be measured and has not been treated with radiation.I have had cancer before, but it was either skin cancer treated successfully, localized prostate cancer, or another type that meets certain criteria.I have not received a live vaccine recently.I have recently been treated with specific drugs for HER2-positive cancer.I can take care of myself but might not be able to do heavy physical work.I have used immunosuppressive therapy recently.I weigh more than 30 kg.I finished my radiation therapy at least 2 weeks ago.I do not have any current infections.I have a history of certain blood disorders.I do not have uncontrolled diabetes, lung disease, or serious GI issues causing diarrhea.My brain metastases have been stable for at least 1 month after treatment.I have or had an autoimmune or inflammatory disorder.I have had a recent blood clot in my lung or deep veins.I am currently being treated for an infection.I am 18 years old or older.My diagnosis fits one of the specific criteria for the 5 study groups.My organs and bone marrow are functioning well.I finished my last cancer treatment more than 2 weeks ago.I have not been treated with CD47 or SIRPα-targeting drugs.I haven't had cancer treatment recently.
- Group 1: IMM2902
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
What is the current enrollment rate for this research endeavor?
"Affirmative, the clinical trial is still in motion and looking for participants. According to information on clinicaltrials.gov, this study was first posted on June 20th 2022 with its most recent update happening July 21st 2022. The investigators are seeking 135 patients from 3 sites."
To what extent can IMM2902 be detrimental to individuals?
"Our team at Power has assigned a score of 1 to IMM2902 due its status as a Phase 1 trial, indicating that there is currently scant data available on the efficacy and safety of this medication."
Are there any remaining vacancies for participants in this experiment?
"Indeed, the information posted on clinicaltrials.gov indicates this trial is currently open for recruitment, having been initially listed on June 20th 2022 and last updated July 21st. The study aims to onboard 135 patients from three distinct sites."
Share this study with friends
Copy Link
Messenger